Literature DB >> 17880866

Dopamine hypothesis of schizophrenia: making sense of it all.

Mitsuru Toda1, Anissa Abi-Dargham.   

Abstract

The dopamine (DA) hypothesis of schizophrenia has evolved over the last decade from the stage of circumstantial evidence related to clinical observations and empirical validation from antipsychotic treatment to finally reach more direct testing and validation from imaging studies. These have provided much information that allows us at this point to assemble all the pieces and attempt to synthesize them and integrate them with the other neurotransmitter alterations observed in this illness. Although clearly not sufficient to explain the complexity of this disorder, the DA dysregulation offers a direct relationship to symptoms and to their treatment. We will review here its history, validation, and implications for treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880866     DOI: 10.1007/s11920-007-0041-7

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  87 in total

Review 1.  The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.

Authors:  Peter S Talbot; Marc Laruelle
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

Review 2.  The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum.

Authors:  D Joel; I Weiner
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

3.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

4.  Brain dopamine d1 receptors in twins discordant for schizophrenia.

Authors:  Jussi Hirvonen; Theo G M van Erp; Jukka Huttunen; Sargo Aalto; Kjell Någren; Matti Huttunen; Jouko Lönnqvist; Jaakko Kaprio; Tyrone D Cannon; Jarmo Hietala
Journal:  Am J Psychiatry       Date:  2006-10       Impact factor: 18.112

Review 5.  Working memory dysfunction in schizophrenia.

Authors:  P S Goldman-Rakic
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

6.  Altered prefrontal dopaminergic function in chronic recreational ketamine users.

Authors:  Rajesh Narendran; W Gordon Frankle; Richard Keefe; Roberto Gil; Diana Martinez; Mark Slifstein; Lawrence S Kegeles; Peter S Talbot; Yiyun Huang; Dah-Ren Hwang; Leyla Khenissi; Thomas B Cooper; Marc Laruelle; Anissa Abi-Dargham
Journal:  Am J Psychiatry       Date:  2005-12       Impact factor: 18.112

7.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

8.  Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors.

Authors:  M Y Zhu; A V Juorio; I A Paterson; A A Boulton
Journal:  Eur J Pharmacol       Date:  1993-07-20       Impact factor: 4.432

9.  Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

Authors:  Stephen McGowan; Andrew D Lawrence; Tim Sales; Digby Quested; Paul Grasby
Journal:  Arch Gen Psychiatry       Date:  2004-02

10.  Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1.

Authors:  Mei-Chun Hsiao; Kun-Ju Lin; Chia-Yih Liu; Kai-Yuan Tzen; Tzu-Chen Yen
Journal:  Schizophr Res       Date:  2003-12-01       Impact factor: 4.939

View more
  69 in total

Review 1.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

Review 2.  Potential programming of dopaminergic circuits by early life stress.

Authors:  Ana-João Rodrigues; Pedro Leão; Miguel Carvalho; Osborne F X Almeida; Nuno Sousa
Journal:  Psychopharmacology (Berl)       Date:  2010-11-19       Impact factor: 4.530

Review 3.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

4.  Corrigendum to "On the integrity of functional brain networks in schizophrenia, Parkinson's disease, and advanced age: Evidence from connectivity-based single-subject classification."

Authors:  Rachel N Pläschke; Edna C Cieslik; Veronika I Müller; Felix Hoffstaedter; Anna Plachti; Deepthi P Varikuti; Mareike Goosses; Anne Latz; Svenja Caspers; Christiane Jockwitz; Susanne Moebus; Oliver Gruber; Claudia R Eickhoff; Kathrin Reetz; Julia Heller; Martin Südmeyer; Christian Mathys; Julian Caspers; Christian Grefkes; Tobias Kalenscher; Robert Langner; Simon B Eickhoff
Journal:  Hum Brain Mapp       Date:  2018-11       Impact factor: 5.038

5.  Activation of brainstem and midbrain nuclei during cognitive control in medicated patients with schizophrenia.

Authors:  Stefanie Köhler; Gerd Wagner; Karl-Jürgen Bär
Journal:  Hum Brain Mapp       Date:  2018-09-05       Impact factor: 5.038

6.  Visual event-related potentials as markers of hyperarousal in Gulf War illness: evidence against a stress-related etiology.

Authors:  Gail D Tillman; Clifford S Calley; Timothy A Green; Virginia I Buhl; Melanie M Biggs; Jeffrey S Spence; Richard W Briggs; Robert W Haley; Michael A Kraut; John Hart
Journal:  Psychiatry Res       Date:  2012-11-11       Impact factor: 3.222

7.  Effects of a GWAS-Supported Schizophrenia Variant in the DRD2 Locus on Disease Risk, Anhedonia, and Prefrontal Cortical Thickness.

Authors:  Margarita V Alfimova; Nikolay V Kondratyev; Alexander S Tomyshev; Irina S Lebedeva; Tatyana V Lezheiko; Vasiliy G Kaleda; Lilia I Abramova; Vera E Golimbet
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

Review 8.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 9.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

10.  Gene- and evidence-based candidate gene selection for schizophrenia and gene feature analysis.

Authors:  Jingchun Sun; Leng Han; Zhongming Zhao
Journal:  Artif Intell Med       Date:  2009-11-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.